Dynomics
Dynomics: Precision drug development for heart function, leveraging HeartDyno, our predictive discovery engine, to improve heart failure treatments.
Founded
2020Dynomics: Precision drug development for heart function, leveraging HeartDyno, our predictive discovery engine, to improve heart failure treatments.
Dynomics was founded with the mission to revolutionize heart failure treatment through precision drug development. The company focuses on targeting therapeutics to human heart function, employing a data-driven approach powered by its proprietary HeartDyno discovery engine. HeartDyno utilizes engineered human cardiac organoids to uncover novel therapeutic targets and candidates, aiming to offer superior efficacy and safety profiles. Dynomics' market focus is on developing targeted therapies to eliminate heart failure, addressing the critical need for better treatment options beyond symptomatic relief.
Notable affiliated people and investors include experts in cardiology and biotechnology, though specific names are not provided. Key achievements of Dynomics include the scalable deployment of HeartDyno, which has significantly advanced the discovery of effective heart failure treatments. The overall impact of Dynomics lies in its potential to improve prognosis for heart failure patients by developing therapies that restore heart function, thereby addressing a leading cause of death globally.
Companies similar to Dynomics include Organos, Dynocardia, Ventrinova and Cydan.
Dynomics was founded in 2020.
Dynomics' headquarters is located in San Mateo, CA, US.
Dynomics' most recent funding round was for $500k (USD) in October 2020.
As of Oct 17, 2020, Dynomics has disclosed funding of $500k (USD). Undisclosed round amounts are excluded.
Dynomics has 11 employees as of Feb 4, 2024.
cydanco.com
